|
| 仁度生物(688193)限售解禁 | | 解禁日期 | 本期流通股本
(万股) | 本期流通股本占
总股本比例(%) | 已流通股本
(万股) | 未流通股本
(万股) | 流通A股
(万股) | 流通A股占
总股本比例(%) | 限售股类型 | | 2025-09-30 | 843.16 | 21.08% | 4000.00 | 0.00 | 3025.76 | 75.64% | 追加承诺限售股份上市流通 | | 2025-03-31 | 131.08 | 3.28% | 3156.84 | 843.16 | 3025.76 | 75.64% | 首发原股东限售股份 | | 2024-04-01 | 50.00 | 1.25% | 3025.76 | 974.24 | 3025.76 | 75.64% | 首发战略配售股份 | | 2023-03-30 | 2121.63 | 53.04% | 2975.76 | 1024.24 | 860.62 | 21.52% | 首发原股东限售股份,首发战略配售股份 | | 2022-09-30 | 35.96 | 0.90% | 860.62 | 3139.38 | 860.62 | 21.52% | 首发机构配售股份 | | 2022-03-30 | 818.16 | 20.45% | 818.16 | 3181.84 | 818.16 | 20.45% | 首发一般股份 |
|